(VIANEWS) – NVIDIA (NVDA), DexCom (DXCM), MiMedx Group (MDXG) are the highest sales growth and return on equity stocks on this list.
Here is a list of stocks with an above 5% expected next quarter sales growth, and a 3% or higher return on equity. May these stocks be a good medium-term investment option?
1. NVIDIA (NVDA)
195.1% sales growth and 69.17% return on equity
NVIDIA Corporation provides graphics, and compute and networking solutions in the United States, Taiwan, China, and internationally. The company's Graphics segment offers GeForce GPUs for gaming and PCs, the GeForce NOW game streaming service and related infrastructure, and solutions for gaming platforms; Quadro/NVIDIA RTX GPUs for enterprise workstation graphics; vGPU software for cloud-based visual and virtual computing; automotive platforms for infotainment systems; and Omniverse software for building 3D designs and virtual worlds. Its Compute & Networking segment provides Data Center platforms and systems for AI, HPC, and accelerated computing; Mellanox networking and interconnect solutions; automotive AI Cockpit, autonomous driving development agreements, and autonomous vehicle solutions; cryptocurrency mining processors; Jetson for robotics and other embedded platforms; and NVIDIA AI Enterprise and other software. The company's products are used in gaming, professional visualization, datacenter, and automotive markets. NVIDIA Corporation sells its products to original equipment manufacturers, original device manufacturers, system builders, add-in board manufacturers, retailers/distributors, independent software vendors, Internet and cloud service providers, automotive manufacturers and tier-1 automotive suppliers, mapping companies, start-ups, and other ecosystem participants. It has a strategic collaboration with Kroger Co. NVIDIA Corporation was incorporated in 1993 and is headquartered in Santa Clara, California.
Earnings Per Share
As for profitability, NVIDIA has a trailing twelve months EPS of $7.6.
PE Ratio
NVIDIA has a trailing twelve months price to earnings ratio of 63.32. Meaning, the purchaser of the share is investing $63.32 for every dollar of annual earnings.
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 69.17%.
Earnings Before Interest, Taxes, Depreciation, and Amortization
NVIDIA’s EBITDA is 155.24.
Previous days news about NVIDIA(NVDA)
- According to Zacks on Monday, 27 November, "Beauty (ELF Quick QuoteELF – Free Report) , Novo Nordisk (NVO Quick QuoteNVO – Free Report) and NVIDIA (NVDA Quick QuoteNVDA – Free Report) have been selected as the top picks with a high net income ratio."
2. DexCom (DXCM)
27.5% sales growth and 18.42% return on equity
DexCom, Inc., a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company provides its systems for use by people with diabetes, as well as for use by healthcare providers. Its products include Dexcom G6 and Dexcom G7, integrated CGM systems for diabetes management; Dexcom Share, a remote monitoring system; Dexcom Real-Time API, which enables authorized third-party software developers to integrate real-time CGM data into their digital health apps and devices; and Dexcom ONE, that is designed to replace finger stick blood glucose testing for diabetes treatment decisions. The company has a collaboration and license agreement with Verily Life Sciences LLC and Verily Ireland Limited to develop blood-based or interstitial glucose monitoring products. It markets its products directly to endocrinologists, physicians, and diabetes educators. The company was incorporated in 1999 and is headquartered in San Diego, California.
Earnings Per Share
As for profitability, DexCom has a trailing twelve months EPS of $0.91.
PE Ratio
DexCom has a trailing twelve months price to earnings ratio of 127. Meaning, the purchaser of the share is investing $127 for every dollar of annual earnings.
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 18.42%.
Yearly Top and Bottom Value
DexCom’s stock is valued at $115.57 at 04:22 EST, way below its 52-week high of $139.55 and way above its 52-week low of $74.75.
Previous days news about DexCom(DXCM)
- According to Zacks on Tuesday, 28 November, "One other Medical stock that has outperformed the sector so far this year is DexCom (DXCM Quick QuoteDXCM – Free Report) . ", "Investors interested in the Medical sector may want to keep a close eye on Connect Biopharma Holdings Limited Sponsored ADR and DexCom as they attempt to continue their solid performance."
- According to Zacks on Tuesday, 28 November, "Some better-ranked stocks in the broader medical space are Haemonetics (HAE Quick QuoteHAE – Free Report) and DexCom (DXCM Quick QuoteDXCM – Free Report) , each carrying a Zacks Rank #2 (Buy). "
- According to Zacks on Tuesday, 28 November, "Amphastar Pharmaceuticals currently sports a Zacks Rank #1 (Strong Buy), and DexCom and Medpace carry a Zacks Rank #2 (Buy). ", "Shares of Amphastar Pharmaceuticals, DexCom and Medpace have gained 91.4%, 2.4% and 32.5%, respectively, in the past year."
- According to Zacks on Tuesday, 28 November, "While Insulet presently sports a Zacks Rank #1 (Strong Buy), Haemonetics and DexCom each carry a Zacks Rank #2 (Buy). "
- According to Zacks on Wednesday, 29 November, "While Insulet presently sports a Zacks Rank #1 (Strong Buy), DexCom carries a Zacks Rank #2. "
3. MiMedx Group (MDXG)
24.4% sales growth and 5.2% return on equity
MiMedx Group, Inc. develops and distributes placental tissue allografts for various sectors of healthcare. It processes the human placental tissues utilizing its patented and proprietary PURION process to produce allografts. The company's patented and proprietary processing method employs aseptic processing techniques in addition to terminal sterilization. Its products include EpiFix, a semi-permeable protective barrier membrane product used for the treatment of chronic wounds, including diabetic foot ulcers, venous leg ulcers, pressure ulcers, and burns; AmnioFix, a semi-permeable protective barrier membrane product for the treatment of wounds related to surgical procedures; EpiCord and AmnioCord that are dehydrated human umbilical cord allografts intended for homologous applications; and AmnioFill that consists of particles of connective tissue matrix derived from placental disc and placental membranes. The company's products have applications primarily in the areas of wound care, burn, surgical, and non-operative sports medicine sectors of healthcare. It also sells allografts for dental applications on an original equipment manufacturer basis. The company sells its products through direct sales force and independent sales agents, as well as through independent distributors primarily in the United States. MiMedx Group, Inc. is headquartered in Marietta, Georgia.
Earnings Per Share
As for profitability, MiMedx Group has a trailing twelve months EPS of $-0.02.
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 5.2%.
Revenue Growth
Year-on-year quarterly revenue growth grew by 20.7%, now sitting on 309.02M for the twelve trailing months.
4. Hercules Technology Growth Capital (HTGC)
16.8% sales growth and 18.57% return on equity
Hercules Capital, Inc. is a business development company. The firm specializing in providing venture debt, debt, senior secured loans, and growth capital to privately held venture capital-backed companies at all stages of development from startups, to expansion stage including select publicly listed companies and select special opportunity lower middle market companies that require additional capital to fund acquisitions, recapitalizations and refinancing and established-stage companies. The firm provides growth capital financing solutions for capital extension; management buy-out and corporate spin-out financing solutions; company, asset specific, or intellectual property acquisition financing; convertible, subordinated and/or mezzanine loans; domestic and international corporate expansion; vendor financing; revenue acceleration by sales and marketing development, and manufacturing expansion. It provides asset-based financing with a focus on cash flow; accounts receivable facilities; equipment loans or leases; equipment acquisition; facilities build-out and/or expansion; working capital revolving lines of credit; inventory. The firm also provides bridge financing to IPO or mergers and acquisitions or technology acquisition; dividend recapitalizations and other sources of investor liquidity; cash flow financing to protect against share price volatility; competitor acquisition; pre-IPO financing for extra cash on the balance sheet; public company financing to continue asset growth and production capacity; short-term bridge financing; and strategic and intellectual property acquisition financings. It also focuses on customized financing solutions, emerging growth, mid venture, and late venture financing. The firm invests primarily in structured debt with warrants and, to a lesser extent, in senior debt and equity investments. The firm generally seeks to invest in companies that have been operating for at least six to 12 months prior to the date of their investment. It prefers to invest in technology, energy technology, sustainable and renewable technology, and life sciences. Within technology the firm focuses on advanced specialty materials and chemicals; communication and networking, consumer and business products; consumer products and services, digital media and consumer internet; electronics and computer hardware; enterprise software and services; gaming; healthcare services; information services; business services; media, content and information; mobile; resource management; security software; semiconductors; semiconductors and hardware; and software sector. Within energy technology, it invests in agriculture; clean technology; energy and renewable technology, fuels and power technology; geothermal; smart grid and energy efficiency and monitoring technologies; solar; and wind. Within life sciences, the firm invests in biopharmaceuticals; biotechnology tools; diagnostics; drug discovery, development and delivery; medical devices and equipment; surgical devices; therapeutics; pharma services; and specialty pharmaceuticals. It also invests in educational services. The firm invests primarily in United States based companies and considers investment in the West Coast, Mid-Atlantic regions, Southeast and Midwest; particularly in the areas of software, biotech and information services. The firm prefers to invest between $10 million to $250 million in equity per transactions. It invests generally between $1 million to $40 million in companies focused primarily on business services, communications, electronics, hardware, and healthcare services. The firm invests primarily in private companies but also have investments in public companies. For equity investments, the firm seeks to represent a controlling interest in its portfolio companies which may exceed 25% of the voting securities of such companies. The firm seeks to invest a limited portion of its assets in equipment-based loans to early-stage prospective portfolio companies. These loans are generally for amounts up to $3 million but may be up to $15 million for certain energy technology venture investments. The firm allows certain debt investments have the right to convert a portion of the debt investment into equity. It also co-invests with other private equity firms. The firm seeks to exit its investments through initial public offering, a private sale of equity interest to a third party, a merger or an acquisition of the company or a purchase of the equity position by the company or one of its stockholders. The firm has structured debt with warrants which typically have maturities of between two and seven years with an average of three years; senior debt with an investment horizon of less than three years; equipment loans with an investment horizon ranging from three to four years; and equity related securities with an investment horizon ranging from three to seven years. The firm prefers to invest through its balance sheet capital. The firm formerly known as Hercules Technology Growth Capital, Inc. Hercules Capital, Inc. was founded in December 2003 and is based in Palo Alto, California with additional offices in Connecticut; Boston, Massachusetts; San Diego, California; Westport, Connecticut; Elmhurst, Illinois; Santa Monica, California; McLean, Virginia; New York, New York; Radnor, Pennsylvania; and Washington, District of Columbia and London, United Kingdom.
Earnings Per Share
As for profitability, Hercules Technology Growth Capital has a trailing twelve months EPS of $2.
PE Ratio
Hercules Technology Growth Capital has a trailing twelve months price to earnings ratio of 7.85. Meaning, the purchaser of the share is investing $7.85 for every dollar of annual earnings.
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 18.57%.
5. Heritage Insurance Holdings (HRTG)
14.3% sales growth and 19.97% return on equity
Heritage Insurance Holdings, Inc., through its subsidiaries, provides personal and commercial residential insurance products. The company offers personal residential property insurance for single-family homeowners and condominium owners, and rental property insurance in the states of Alabama, California, Connecticut, Delaware, Florida, Georgia, Hawaii, Maryland, Massachusetts, Mississippi, New Jersey, New York, North Carolina, Rhode Island, South Carolina, and Virginia; commercial residential insurance for properties in Florida, New Jersey, and New York; and licensed in the state of Pennsylvania, as well as personal residential and wind-only property insurance. It also provides restoration, and emergency and recovery services; and property management, and reinsurance services. The company writes personal line policies through a network of retail independent agents, wholesale agents, and a partnership with a direct agency, as well as indirectly to approximately 1,500 retail locations through eight wholesale agency relationships; and personal and commercial insurance policies through a network of approximately 70 independent agencies. Heritage Insurance Holdings, Inc. was founded in 2012 and is headquartered in Tampa, Florida.
Earnings Per Share
As for profitability, Heritage Insurance Holdings has a trailing twelve months EPS of $0.98.
PE Ratio
Heritage Insurance Holdings has a trailing twelve months price to earnings ratio of 7.4. Meaning, the purchaser of the share is investing $7.4 for every dollar of annual earnings.
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 19.97%.
6. FTI Consulting (FCN)
10.1% sales growth and 13.72% return on equity
FTI Consulting, Inc. provides business advisory services to manage change, mitigate risk, and resolve disputes worldwide. The company operates through five segments: Corporate Finance & Restructuring, Forensic and Litigation Consulting, Economic Consulting, Technology, and Strategic Communications. Its Corporate Finance & Restructuring segment provides business transformation, transactions, and turnaround and restructuring services. The company's Forensic and Litigation Consulting segment offers. construction and environmental solution, data and analytics, dispute, health solution, and risk and investigation services. Its Economic Consulting segment provides. antitrust and competition economic, financial economic, and international arbitration services. The company's Technology segment offers corporate legal operation; e-discovery and expertise; and information governance, privacy, and security services. Its Strategic Communications segment provides corporate reputation, financial communication, and public affairs services. The company serves aerospace and defense, agriculture, airlines and aviation, automotive and industrial, construction, energy, power and products, environmental solutions, financial services, healthcare and life sciences, hospitality, gaming and leisure, insurance, mining, private equity, public sector, real estate, retail and consumer products, telecom, media and technology, and transportation and logistics industries. The company was founded in 1982 and is headquartered in Washington, District of Columbia.
Earnings Per Share
As for profitability, FTI Consulting has a trailing twelve months EPS of $6.76.
PE Ratio
FTI Consulting has a trailing twelve months price to earnings ratio of 32.92. Meaning, the purchaser of the share is investing $32.92 for every dollar of annual earnings.
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 13.72%.
Moving Average
FTI Consulting’s value is way higher than its 50-day moving average of $191.93 and way higher than its 200-day moving average of $187.63.
Earnings Before Interest, Taxes, Depreciation, and Amortization
FTI Consulting’s EBITDA is 2.45.
Volume
Today’s last reported volume for FTI Consulting is 258748 which is 29.09% above its average volume of 200428.
Revenue Growth
Year-on-year quarterly revenue growth grew by 15.1%, now sitting on 3.34B for the twelve trailing months.
7. The Pennant Group (PNTG)
9.6% sales growth and 10.04% return on equity
The Pennant Group, Inc. provides healthcare services in the United States. It operates in two segments, Home Health and Hospice Services, and Senior Living Services. The company offers home health services, including clinical services, such as nursing, speech, occupational and physical therapy, medical social work, and home health aide services; and hospice services comprising clinical care, education, and counseling services for the physical, spiritual, and psychosocial needs of terminally ill patients and their families. It also provides senior living services, such as residential accommodations, activities, meals, housekeeping, and assistance in the activities of daily living to seniors, who are independent or who require some support. As of December 31, 2021, the company operated 88 home health and hospice agencies, and 54 senior living communities with 4127 Senior Living units in Arizona, California, Colorado, Idaho, Iowa, Montana, Nevada, Oklahoma, Oregon, Texas, Utah, Washington, Wisconsin, and Wyoming. The Pennant Group, Inc. was incorporated in 2019 and is headquartered in Eagle, Idaho.
Earnings Per Share
As for profitability, The Pennant Group has a trailing twelve months EPS of $0.42.
PE Ratio
The Pennant Group has a trailing twelve months price to earnings ratio of 33.52. Meaning, the purchaser of the share is investing $33.52 for every dollar of annual earnings.
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 10.04%.
Yearly Top and Bottom Value
The Pennant Group’s stock is valued at $14.08 at 04:22 EST, way under its 52-week high of $16.39 and way above its 52-week low of $9.75.
Revenue Growth
Year-on-year quarterly revenue growth grew by 18.5%, now sitting on 523.6M for the twelve trailing months.
Previous days news about The Pennant Group(PNTG)
- According to Zacks on Monday, 27 November, "This month, The Pennant Group reported its third-quarter 2023 results, where it witnessed solid improvement in its overall top line. "
